李媛媛，理学博士，硕士生青年导师。2019年毕业于武汉大学k1体育，主要从事药物化学以及针对人类重大疾病的创新药物研究。研究思路是以新药研发的难点和临床上尚未满足的重大需求为出发点，以分子识别和构效关系为基础，利用药-靶相互作用特性与药物成药性优势匹配属性、分子模拟、有机合成和分子药理学等技术手段，对发现的先导化合物进行结构优化和作用机制研究，从而开发创新药物。截至目前，主持国家自然科学基金（1项）、贵州省自然科学基金面上项目1项、贵州省青年引导项目1项、湖北省教育厅青年项目1项；已发表SCI论文15篇，其中以第一作者、共同第一作者或通讯作者身份发表9篇，包括Journal of Medicinal Chemistry 4篇、European Journal of Medicinal Chemistry 4篇、Bioorganic Chemistry 1篇；参与申请发明专利3项，其中1项已获授权；获得贵州省药学科学技术奖（排名2）、湖北省科技进步二等奖（排名10）。

研究方向：靶向抗肿瘤药物研究

邮箱：liyy1030@163.com

通讯地址：贵州省贵安新区安康大道6号k1十年体育品牌

近年主持的代表性科研项目：

1.国家自然科学基金，地区科学基金项目，22567011，靶向ERα和KAT6A的双靶点声动降解剂的构建及抗ER+耐药性乳腺癌活性研究，2026.01-2029.12，33万元，在研。

2.贵州省基础研究计划面上项目，黔科合基础MS[2026]525，基于光诱导的ERα降解协同抗炎的双功能小分子的构建及抗耐药性乳腺癌活性研究，2026.01-2028.12，10万元，在研。

3.贵州省青年引导项目，黔科合基础QN[2025]112，基于超声诱导的ERα/KAT6A双靶点降解剂的设计及其克服乳腺癌耐药的作用机制研究2025.01-2027.12，5万元，在研。

4.湖北省教育厅科技研究项目，青年人才项目，Q20201610，靶向雌激素受体和CDK4/6的双靶点抗乳腺癌小分子的构建及活性研究，2020/01-2021/12，2万元，已结题。

代表性研究论文：

1.Yuanyuan Li;Ming Sun;Jie Yu;Wei Jiang;Wei Tian;Xin Chen;Silong Zhang;Huan He.Design of Sonosensitizers Integrated with Resveratrol Motif for Synergetic Sonodynamic Therapy and Nuclear Factor Kappa B Transcription Suppression of Breast Cancer.J. Med. Chem.2023, 66, 6149−6159.

2.Huan He;Ziwei Wang;Xueke Peng;Luolong Qing;Yu Zhang;ShaojuanFu;Juan Xu;Yuanyuan Li*, Silong Zhang*. Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole−Electron Analysis.J. Med. Chem.2024, 67, 1, 543–554.(*Corresponding author)

3.Silong Zhang; Yu Zhang; Xin Chen; Juan Xu; Huaxiang Fang;Yuanyuan Li*; Yi Liu*; Huan He*. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.J. Med. Chem.2022, 65, 23, 15856–15877. (*Corresponding author)

4.Silong Zhang; Yu Zhang; Ziwei Wang; Luolong Qing; Shaojuan Fu; Juan Xu;Yuanyuan Li*; Huaxiang Fang*; Huan He*. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d] pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.Eur. J. Med. Chem.2023, 261, 115836.(*Corresponding author)

5.Yuanyuan Li^#;Qiu Han^#;Qiwen Sun^#;Xue Wang^#;Yunsheng Ran;Yifei Ma;Jiangrong Lu;Ziqi Jin;Jing Huang;Yujie Wang;Jianta Wang;Yue'e Chai;Hongliang Li;Ji-Quan Zhang. Discovery of highly potent mTOR inhibitors aimed at suppressing the progression of acute myeloid leukemia.Bioorg. Chem.2025, 157,108287.(# Co-First Author)

6.Yuanyuan Li^#;Silong Zhang^#; Jing Zhang; Zhiye Hu; Yuan Xiao; Jian Huang; Chune Dong; Shengtang Huang; Hai-bing Zhou.Exploring the PROTAC Degron Candidates: OBHSA with Different Side Chains as Novel Selective Estrogen Receptor Degraders (SERDs).Eur. J. Med. Chem.2019, 172, 48-61. (# Co-First Author)

7.Silong Zhang^#;Yuanyuan Li^#; Tao Li; Yu Zhang; Haimei Li; Zhengzai Cheng; Na Peng; Yi Liu; Juan Xu; Huan He ; Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen,J Med Chem,2022, 65(4): 3632-3643.(^#Co-First Author)

8.Zhiye Hu;Yuanyuan Li^#;Baohua Xie;Wentao Ning;Yuan Xiao;Yuan Huang;Chenxi Zhao;Jian Huang;Chune Dong;Hai-Bing Zhou. Novel Class of 7-Oxabicyclo[2.2.1]heptene Sulfonamides with Long Alkyl Chains Displaying Improved Estrogen Receptor α Degradation Activity.Eur. J. Med. Chem.2019, 182, 11605. (# Co-First Author)

9.Lilan Xin^#; Jian Min^#; Hebing Hu^#;Yuanyuan Li^#; Chuanqian Du; Baohua Xie; Yan Cheng; Xiaofei Deng; Xiangping Deng; Kang Shen; Jian Huang; Chun-Chi Chen; Rey-Ting Guo; Chune Dong; Hai-Bing Zhou.Structure-Guided Identification of Novel Dual-targeting Estrogen Receptor α Degraders with Aromatase Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.Eur. J. Med. Chem.2023,253, 115328.(# Co-First Author)